Anne Dupraz Poiseau and Stuart Mudge examine the European Commission’s proposal for a regulatory framework for human tissue engineered products.
Download the full publication now
Fill in the form to download the content
PublicationCell & Gene Therapy
Regulatory Advanced Therapies in the EU a square Peg in a round hole
All our resources
More resources
Case study
Cell & Gene Therapy
Creating a complex IND whilst safeguarding confidential data between a CGT spin-off and CDMO
When submitting and IND for CGT product/therapy, it’s crucial to confirm that the viral vector in use is appropriate, especially…
blog
Cell & Gene Therapy
Navigating the FDA Draft Guidance Document “Manufacturing Changes and Comparability for Human Cellular and Gene…
In the ever-evolving landscape of pharmaceuticals/biopharmaceuticals, manufacturing changes play a pivotal role in ensuring the quality and effectiveness of medicinal…
webinar
Cell & Gene Therapy
Key CMC and NC considerations for cell and gene therapy development
ATMPs (Advanced Therapeutic Medicinal Products) in Europe, or CGTs (Cell and Gene Therapies) as they are known in the US,…
webinar
Cell & Gene Therapy
Patient access to Advanced Therapies in Europe 2009-2021: from early access failures to current challenges
The recent announcement of BlueBirdBio to wind down its European commercialisation efforts due to access and pricing challenges for its…
